Ghrelin is an important orexigenic hormone that reduces fat oxidation and increases adiposity. This study investigated plasma ghrelin levels in Chinese Uygur patients with chronic obstructive pulmonary disease (COPD). Plasma ghrelin and anabolic and catabolic factors were measured in 38 patients and 24 control subjects. COPD patients were divided into two groups based on body mass index (BMI): underweight (BMI ≤ 20 kg/m2, n = 18) or normoweight (BMI ≤ 20 kg/m2, n = 20). Plasma ghrelin levels were found to be significantly higher in underweight than in normoweight patients or healthy controls. Circulating tumour necrosis factor-α and interleukin-6 concentrations were significantly higher in underweight than in normoweight patients, whereas insulin concentrations were significantly lower. Plasma ghrelin levels correlated negatively with forced expiratory volume in 1 s (FEV1; r = 0.35), but did not significantly correlate with FEV1/forced vital capacity. Plasma ghrelin levels were elevated in underweight COPD patients and were associated with cachexia and abnormal pulmonary function.
Gray-DonaldKGibbonsLShapiroSH: Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med1996; 153: 961–966.
2.
LaabanJPKouchakjiBDoreMF: Nutritional status of patients with chronic obstructive pulmonary disease and acute respiratory failure. Chest1993; 103: 1362–1368.
3.
VandenberghEVan de WoestijneKPGyselenA: Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. Am Rev Respir Dis1967; 95: 556–566.
4.
WilsonDORogersRMWrightEC: Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis1989; 139: 1435–1438.
5.
DonahoeMRogersRM: Nutritional assessment and support in chronic obstructive pulmonary disease. Clin Chest Med1990; 11: 487–504.
6.
ThurlbeckWM: Diaphragm and body weight in emphysema. Thorax1978; 33: 483–487.
7.
DonahoeM: Nutritional support in advanced lung disease. The pulmonary cachexia syndrome. Clin Chest Med1997; 18: 547–561.
8.
ScholsAMSlangenJVolovicsL: Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med1998; 157: 1791–1797.
9.
KojimaMHosodaHDateY: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature1999; 402: 656–660.
10.
SmithRGVan der PloegLHHowardAD: Peptidomimetic regulation of growth hormone secretion. Endocr Rev1997; 18: 621–645.
11.
WrenAMSealLJCohenMA: Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab2001; 86: 5992–5995.
12.
TschopMSmileyDLHeimanML: Ghrelin induces adiposity in rodents. Nature2000; 407: 908–913.
13.
ShiiyaTNakazatoMMizutaM: Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab2002; 87: 240–244.
14.
CummingsDEWeigleDSFrayoRS: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med2002; 346: 1623–1630.
15.
GarciaJMPolvinoW: Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: Results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist2007; 12: 594–600.
ItohTNagayaNYoshikawaM: Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med2004; 170: 879–882.
18.
Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report, updated 2005. Bethesda: National Heart, Lung and Blood Institute, 2005. GOLDWkshp05Clean.pdf. Available at: www.goldcopd.com/download.asp?intID=231. Accessed 28 June 2006.
19.
CelliBRMacNeeW: Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J2004; 23: 932–946.
20.
HosodaHKojimaMMatsuoH: Ghrelin and des-acyl ghrelin: Two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun2000; 279: 909–913.
21.
WrenAMSmallCJWardHL: The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology2000; 141: 4325–4328.
22.
NagayaNUematsuMKojimaM: Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation2001; 104: 1430–1435.
23.
NearyNMSmallCJWrenAM: Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab2004; 89: 2832–2836.
24.
DeBoerMDZhuXXLevasseurP: Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology2007; 148: 3004–3012.
25.
NagayaNItohTMurakamiS: Treatment of cachexia with ghrelin in patients with COPD. Chest2005; 128: 1187–1193.
26.
GnanapavanSKolaBBustinSA: The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab2002; 87: 2988–2991.
27.
MarcoraSMChesterKRMittalG: Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr2006; 84: 1463–1472.
